Sarah van Hellenberg Hubar-Fisher Takes Charge as Interim CEO
In a significant move, Bioretec Ltd has announced the appointment of Sarah van Hellenberg Hubar-Fisher as the company's interim CEO. This decision comes as the company transitions towards a new growth phase in the evolving field of medical devices.
Background of the New Leadership
Van Hellenberg Hubar-Fisher, who holds an MBA, has a wealth of experience, bringing over 23 years of expertise from her leadership roles in the global healthcare sector. Her experience includes successfully introducing innovative technologies aimed at improving patient care. This extensive background positions her to effectively steer Bioretec as it focuses on becoming a leading provider of absorbable orthopedic implants on a global scale.
Commentary from Company Officials
Kustaa Poutiainen, Chair of the Board of Directors at Bioretec, expressed his enthusiasm regarding the new leadership. He stated, "CEO Sarah van Hellenberg Hubar-Fisher starts the new growth phase for Bioretec. We are keen to leverage her considerable expertise to enhance our position in the orthopedic industry."
Strategic Vision and Goals
In her own words, van Hellenberg Hubar-Fisher shared her excitement about leading Bioretec into this new chapter. She emphasized the company’s ambition to achieve market leadership and deliver high-quality, reliable absorbable implants to patients who need them. This strategic approach is likely to drive advancements in surgical care and improve patient outcomes.
Key Initiatives and Product Offerings
Bioretec is rapidly advancing its RemeOs™ product line, featuring innovative magnesium alloy and hybrid composite materials. These implants are designed to absorb and integrate with bone tissue over time, negating the need for additional removal surgeries. As this product line continues to receive regulatory approvals, including market authorization in the U.S. and CE mark approval in Europe, Bioretec aims to significantly impact the global orthopedic trauma and spine market, valued at over USD 9 billion.
Company Overview
Bioretec operates out of Finland and is recognized for pioneering the use of biodegradable orthopedic implants. The company’s focus on the biological interface of active implants aims to enhance bone growth and expedite fracture healing. Bioretec's innovative products are currently utilized in around 40 countries across the globe, underscoring the company's international reach and commitment to excellence.
Contact Information
For further information, individuals can reach out to Kustaa Poutiainen, Chair of the Board, at +358 40 042 4506. The Nordic Certified Adviser AB, another key contact, can be reached at +46 70 551 67 29.
Frequently Asked Questions
What is Bioretec?
Bioretec is a Finnish medical device company specializing in biodegradable orthopedic implants.
Who has been appointed as the new interim CEO?
Sarah van Hellenberg Hubar-Fisher has been named the interim CEO of Bioretec.
What are RemeOs™ products?
RemeOs™ are biodegradable implants that facilitate fracture healing and are designed to be absorbed by the body, eliminating the need for removal surgery.
What is Bioretec's goal in the orthopedic market?
Bioretec aims to become a leader in the absorbable orthopedic implants sector and improve patient care and outcomes.
How can I contact Bioretec for more information?
Individuals can contact Kustaa Poutiainen at +358 40 042 4506 for inquiries related to Bioretec.
